CLOVIS ONCOLOGY INC's ticker is CLVS and the CUSIP is 189464100. A total of 105 filers reported holding CLOVIS ONCOLOGY INC in Q3 2022. The put-call ratio across all filers is 0.57 and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2022 | $64,000 | -63.2% | 53,447 | -16.7% | 0.01% | -66.7% |
| Q4 2021 | $174,000 | -63.1% | 64,126 | -39.3% | 0.02% | -56.1% |
| Q3 2021 | $471,000 | -52.8% | 105,562 | -38.6% | 0.04% | -57.7% |
| Q2 2021 | $998,000 | +101.2% | 171,994 | +102.2% | 0.10% | +14.1% |
| Q3 2020 | $496,000 | +93.8% | 85,075 | +246.2% | 0.08% | +240.0% |
| Q4 2019 | $256,000 | +19.1% | 24,572 | +183.4% | 0.02% | +108.3% |
| Q1 2019 | $215,000 | -68.2% | 8,669 | +5.6% | 0.01% | -63.6% |
| Q3 2017 | $676,000 | – | 8,209 | – | 0.03% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Versant Venture Management, LLC | 814,833 | $60,485,054,000 | 53.20% |
| Palo Alto Investors LP | 2,121,857 | $157,505,000 | 7.79% |
| NEA Management Company, LLC | 2,279,781 | $169,228,000 | 7.65% |
| EcoR1 Capital, LLC | 243,048 | $18,041,000 | 6.01% |
| Redmile Group, LLC | 900,879 | $66,872,000 | 6.00% |
| Opaleye Management Inc. | 140,000 | $10,392,000 | 4.82% |
| PFM Health Sciences, LP | 2,266,756 | $168,261,000 | 4.64% |
| Partner Investment Management, L.P. | 40,798 | $3,028,000 | 4.56% |
| CLIFTON PARK CAPITAL MANAGEMENT, LLC | 826,919 | $61,383,000 | 3.74% |
| Opus Point Partners Management, LLC | 55,988 | $4,156,000 | 3.48% |